My Profile   |   Print Page   |   Contact Us   |   Sign In   |   Register
ASAP Blog
Blog Home All Blogs
Welcome to ASAP Blog, the best place to stay current regarding upcoming events, member companies, the latest trends, and leaders in the industry. Blogs are posted at least once a week; members may subscribe to receive notifications when new blogs are posted by clicking the "Subscribe" link above.

 

Search all posts for:   

 

Top tags: alliance management  alliances  collaboration  partnering  alliance  alliance managers  partners  partner  alliance manager  partnerships  ecosystem  The Rhythm of Business  partnership  Jan Twombly  governance  biopharma  Eli Lilly and Company  Vantage Partners  Strategic Alliance Magazine  IBM  IoT  ASAP BioPharma Conference  strategy  healthcare  NetApp  2015 ASAP Global Alliance Summit  Christine Carberry  Cisco  cloud  communication 

Pharma Alliance Leaders Making Adjustments to a Virtual, Stay-at-Home World

Posted By Michael J. Burke, Tuesday, April 28, 2020

During the COVID-19 crisis, it’s been heartening to see how many pharmaceutical companies—including a representative number of ASAP members—have stepped up their efforts to work toward vaccines and medicines to treat the virus, including partnering with one another and with government to speed up the processes of research and development, all while trying to keep regular manufacturing and supply operations going so that lifesaving drugs continue to reach patients who need them.

But as is true for all of us, the coronavirus has thrown significant obstacles in pharma companies’ path as well: Almost everyone is working from home, supply chains have been interrupted, sales reps can’t see physicians, and some companies in the biopharma ecosystem are already feeling the pain of financial distress.

So how are pharma alliance management groups coping with COVID? How are their teams communicating internally, reaching out to partners, and moving projects forward in the face of these hurdles?

Different Times, Different Strategies

That was the subject of an April 21 ASAP Netcast Webinar, “Alliance Management Practices in a Virtual World for Pharmaceutical Executives.” The four panelists were among the crème de la crème of big-pharma alliance leaders: Harm-Jan Borgeld, CSAP, PhD, MBA, vice president and head of alliance management for Merck Healthcare KGaA; Mark Coflin, CSAP, MBA, vice president and head of global alliance management at Takeda; David Thompson, CSAP, chief alliance officer at Eli Lilly and Company; and Steve Twait, CSAP, vice president of alliance and integration management at AstraZeneca. The webinar was moderated by Michael Leonetti, CSAP, president and CEO of ASAP.

As Leonetti noted at the outset, “We are in very different times, and different times require different strategies.” Accordingly, the four alliance leaders shared their strategies and thinking in a number of areas, from keeping their teams humming along internally to communicating with partners to monitoring supply chain and manufacturing issues.

Thompson observed that we’re currently living through a “worldwide inflection point,” a phenomenon not seen “since probably the 1930s and ’40s, where the entire world is experiencing something at the same time.” Twait concurred: “This is my 20th year in the alliance management space and I can say I have never seen anything quite like this before. COVID-19 is providing us with challenges I don’t think any of us ever anticipated.”

Buddies, Backups, and Break Times

Borgeld said one of the first things he and his colleagues at Merck in Germany did was to look at what would happen if alliance managers could not fulfill their duties, for whatever reason. So they created “a buddy system, where every alliance manager has a backup—even me. A member of the leadership team is my backup in case I would not be able to function. Also the partners have been informed of this backup system, so they know there’s always someone to contact.”

In this new world, alliance executives and their teams have had to figure out how to hold internal meetings virtually—and how often and for how long—how to carry out alliance governance, and how to interface with partners when everyone is working remotely and none of these activities can be done in person. Some of what they’ve done has changed over time already—going from two meetings a week down to one, for example, having shorter meetings, or making the meetings last only 45 minutes instead of an hour, both to give people a much-needed break that they might have formerly used to walk down the hall and “grab a cup of coffee,” as Twait put it, but also to allow for some “unstructured chat” time, in Thompson’s words.

In addition, half-day or full-day meetings across multiple time zones around the world have in many cases been condensed down to one- or two-hour videoconferences, which allows greater focus and prevents “virtual meeting burnout” while being “respectful of time zones,” as Coflin phrased it—especially important when partners and/or team members may be spread out across the globe.

There’s good and bad in this virtual situation, according to Thompson. “The upside of course is there’s a time savings, the downside is you’re not getting that human interaction,” he said. “You have to be more cognizant of how you’re going to structure your agendas for the meeting to get the most out of it.” Another positive that Twait has observed is that videoconferences today give us a window into each other’s lives—including children, pets, decorations in home offices or other rooms—and these help to build “interpersonal trust” in a way that wasn’t necessarily done pre-COVID.

Borgeld emphasized that while some of the same problems and issues arose before the virus took hold, now it’s even more critical to anticipate and address them, whether it’s coworkers who are trying to multitask and get work done while managing children at home, or partners who may be experiencing financial distress. In the latter case, he recommended, “Seek the dialogue early—it’s not important that you open the books. Focus on the alliance itself: what do we need to do? Come early, discuss it, and try to find a solution.”

Problems, Solutions, and Opportunities

Solutions can be hard to come by, especially where coronavirus is concerned, but more than one of the panelists mentioned the resourceful, flexible cooperation and collaboration between various biopharma organizations, leading to more partnerships and, hopefully, effective treatments and vaccines down the road.

“One of the things that’s very encouraging is the number of partnerships that are springing up all over,” said Twait. “Not just between pharma and pharma—we’re all working together, and many of those interests are around COVID. I’m seeing pharma to biotech, pharma to academia, pharma and others to nonprofits—partnerships of all types.”

Coflin backed up that assessment: “In this current environment where we’re looking for solutions on an urgent basis for humanity, there’s a lot of external innovations and partnerships that are rapidly forming, amongst companies, together with regulatory authorities, NIH, you name it. Everybody’s pulling together to find some solutions.”

Twait emphasized viewing the crisis as a chance to potentially change how things are being done for the better. “I try to look for the opportunities that are coming out of this, and it feels like now is the perfect time,” he explained. “What COVID is allowing us to do is to ask the question: Can we move faster, and are there ways to accelerate? It’s a great opportunity to use this burning platform and the urgency that we have to really challenge inefficiencies and change some of those internal and external processes.”

Shining Examples

Thompson advised looking at alliances with an eye toward contractual obligations, as well as the risks that may be triggered if those are left unfulfilled. “I would really recommend to everybody,” he said, “to do a thorough read of each contract: to go back through and with the lens of the business, human, and legal uncertainties and risks, foresee what’s in the contract, identify and begin to engage with the partners in a discussion now. To me that has been one of the most helpful exercises we’ve done, and also has allowed us to engage in productive discussions, because we’re identifying early the things that the contracts are pointing to. Regardless if you’re in or out of our industry, anybody who’s got a contractual relationship with anybody, that is worth doing.”

Coflin also mentioned being aware of potential supply issues, which can be dicey at a time like this. “The supply continuity is critical to the patient,” he acknowledged. “These are lifesaving medicines in some cases. So we look very carefully at the supply chain, and have since the very beginning of COVID-19, looking not only at the current inventory but also…where it’s sourced from—in some cases China, [or] Italy, and others where we’ve run into a very challenging situation with logistics. The amount of flights is less than it used to be, including cargo, so it is something that requires constant evaluation of risk and constant discussion with our partners.”

Asked for final thoughts, Borgeld gave this exhortation: “Focus on your team. Make [it] so that they can shine in this difficult environment. It’s an environment where there are challenges, and that has to be recognized. Focus on the team, make sure that the team feels that [its] needs are addressed.”

After the four panelists had answered a number of questions, both from Leonetti and the large audience sitting in on the webinar, Leonetti thanked them for sharing their insights and experiences. “You are a shining example of our community, our willingness to collaborate with each other, and our willingness to help share best practices that ultimately make us better partners and better future partners,” he said. “I can’t thank you all enough for bringing this forward and helping to keep our ASAP community alive during these virtual times.”

Tags:  academia  Alliance Leaders  alliance manager  AstraZeneca  best practices  biotech  COVID-19  David Thompson  Eli Lilly and Company  Harm-Jan Borgeld  manufacturing  Mark Coflin  Merck Healthcare KGaA  partnerships  Pharma  Pharmaceutical Executives  Steve Twait  supply chain  Takeda  virtual 

Share |
PermalinkComments (0)
 

Making Adjustments: ASAP Global Alliance Summit Now in June!

Posted By Michael Leonetti, CSAP, Monday, March 9, 2020

We’ve all had the experience of an unexpected event that suddenly threw a wrench into our alliances or our lives. Depending on the nature of the event, its magnitude, and how close to home it hits, we generally do our best to understand how the landscape has changed, adjust to the implications, make accommodations, and move forward. Reality may defy our hopes and expectations, but we pick up the pieces, dust ourselves off, and keep getting up in the morning amid the now-altered environment.

So it is with the coronavirus, or COVID-19, whose effects worldwide have already proven serious. Our hearts go out to all those who have been directly affected by this virus, especially the families of those who have died from it around the globe. In addition, this contagious disease—and the fear of it—has already had a significant economic impact, including declines in business and vacation travel and the cancellation or postponement of a number of conventions, conferences, and trade shows in various industries. Most organizations have been forced to respond in some way, whether to shift events to alternative dates or from physical to virtual, to curtail travel to safeguard their people, or to try to limit the damage to their bottom line. Or all of the above.

We at ASAP have faced these challenges as well, resulting in the difficult decision to reschedule our Global Alliance Summit, which had been scheduled for next week, to June 23–25 in Tampa, Florida. In the great scheme of things this move may barely register, but for a member organization like ours, as you can imagine, it’s a big deal. Shifting the Summit to new dates has required a huge and immediate lift on the part of ASAP staff and board, which is ongoing as I write this.

The good news is, the show will go on! I’m very happy that we were able to secure the original conference venue, the Renaissance Tampa International Plaza Hotel, for our late-June dates. I’m even more pleased to report that at present, nearly 75 percent of our presenters, panelists, and moderators have confirmed that they’ll be there.

What this means is that we’ll still have a terrific program, as planned—a program that, as always, includes presentations by some of the alliance and partnering profession’s best and brightest minds and leading lights, including these:

  • A keynote presentation by Steve Steinhilber, global vice president, ecosystems and business development, at Equinix: “Creating Alliances and Digital Ecosystem Capabilities in an Increasingly Platform Enabled and Interconnected World.” Steve ran alliances at Cisco for a number of years, and while there authored the influential book Strategic Alliances: Three Ways to Make Them Work (2008). He was also among those interviewed for our Q1 2020 cover story in Strategic Alliance Quarterly on the rise and far-reaching effects of ecosystems in nearly every industry, and his insights into this important and growing area are sure to be valuable and applicable to any industry.
  • A fascinating panel moderated by Adam Kornetsky of Vantage Partners titled “Big Pharma M&A and Alliance Portfolios: What’s at the End of the Rainbow?” This interactive discussion will feature panelists including Mark Coflin, CSAP, vice president and head of global alliances at Takeda Pharmaceuticals; Dana Hughes, vice president of integration management and alliance management at Pfizer; and Jeffrey C. Hurley, senior director, GBD global alliance lead at Takeda. These longtime ASAP members will share their recent M&A experiences, provide insights into how alliance portfolios have been managed through the transaction process, and engage participants in sharing additional perspectives critical for unlocking and maximizing the full value of an alliance portfolio.
  • A presentation by Dan Rippey, director of engineering for Microsoft’s One Commercial Partner program, and Amit Sinha, chief customer officer and cofounder of WorkSpan, called “How the Microsoft Partner-to-Partner Program Is Disrupting the Way Technology Companies Are Leveraging the Power of Ecosystems for Business Growth, Customer Acquisition, and Gaining a Competitive Advantage.” With the rise of ecosystems has come the increasing deployment of partner-to-partner (P2P) programs, and Microsoft’s may be the largest on the planet, connecting partners directly with each other to deliver value to customers without Microsoft’s intervention. Powered by WorkSpan Ecosystem Cloud, this program increases profitability by selling solutions from one or more of Microsoft’s partners, achieving faster time-to-market by leveraging prebuilt joint solutions, closing larger deals, and reaching more customers by co-selling with other Microsoft partners for a bigger joint pipeline. This new model of partnering has wide applicability and Dan and Amit’s description of how it works is a must-hear.
  • Another terrific panel moderated by Jan Twombly, president of The Rhythm of Business, called “Biopharma Commercial Alliance Management Challenges.” Panelists will include Brooke Paige, CSAP, ASAP board chair and former vice president of alliance management at Pear Therapeutics; and David S. Thompson, CSAP, chief alliance officer at Eli Lilly and Company. In the long life of a successful biopharma alliance, the commercialization phase brings its own particular challenges and problems. This panel promises to be a lively discussion of such topics as how alliance managers deliver value in a commercial alliance, considerations for driving alignment in local geographies and at a corporate level, aspects of alliance governance to get right to maximize value, and much more.

I’m not indulging in hyperbole when I say that these are just a very few of the highlights. Again,  more than three-quarters of the original Summit agenda is planned  to remain intact—including preconference workshops, single-speaker presentations, illuminating panel discussions, and of course, valuable networking opportunities.

We know there are many factors governing decisions on where to travel and why—especially under current conditions. But we’re confident that even after shifting to the June dates, we’ll be fielding a stellar lineup at the Summit in Tampa—one you’ll want to be present for. If you haven’t registered yet and/or for whatever reason were uncertain about attending in March, you now have some extra time to decide.

Additionally, the Renaissance has set up a new block of rooms at our discounted rate of $219.00+ per night. To book your room for the new conference dates, please click on the link below:

https://www.marriott.com/event-reservations/reservation-link.mi?id=1583953400577&key=GRP&app=resvlink

Let’s all try to plan for normal again! Won’t you join us? I hope to see you in Tampa!

Tags:  alliances  Amit Sinha  biopharma  Brooke Paige  Dan Rippey  Dana Hughes  David Thompson  Ecosystems  Eli Lilly and Company  Equinix  Jan Twombly  Jeffrey Hurley  Mark Coflin  Microsoft  P2P  partners  Pfizer  Steve Steinhilber  Takeda  The Rhythm of Business  Vantage Partners  WorkSpan 

Share |
PermalinkComments (0)
 

A Lesson From the Whiz Kids: Change and Teams— ‘An Inevitable Combination’

Posted By Cynthia B. Hanson, Monday, July 22, 2019

My father, who recently passed away, worked for Ford Motor Company in its heyday. A 1950  graduate of Harvard Business School and a former Marine in World War II and the Korean War, he started working at  Ford in 1953 and eventually worked under Ford President Robert McNamara, who later became the longest-serving secretary of defense in United States history under Presidents  John F. Kennedy and Lyndon B. Johnson.

 

Ford Motor Company was losing millions in the post-  WWII era, but turned a corner through innovative production and management. Seeking new ways to succeed in a time of rapid change (sound familiar?), the company engaged in a unique partnership with a group of United States Air Force officers. Ford would provide the young men just out of the military with jobs and, in turn, the former officers would revamp the company. Disparagingly dubbed the “Quiz Kids” by fellow employees for their youthful questioning, they renamed themselves the “Whiz Kids.” As a manager in finance, production programming, sales, marketing, personnel, and technical and transportation operations, my father worked under their guidance to help reorganize Ford’s financial framework, redefine corporate culture, and contribute to automotive innovation.

 

After my father’s memorial service, I pored over the books in his library. You can tell a lot about a person from the books he or she reads. Based on the collective mix, he pursued self-education to the end, especially in the areas of business, history, leadership—and the art of fly fishing. The mix included tomes such as Doris Kearns Goodwin’s The Bully Pulpit and Nigel Hamilton’s The Mantle of Command. But what really caught my eye was an unassuming slip of a book: The Wisdom of Teams: Creating the High–Performance Organization, by Jon R. Katzenbach and Douglas K. Smith, Harvard Business School Press, 1993. As I paged through, I found only one sentence in the entire book underlined. In the chapter “Teams and Major Change: An Inevitable Combination,” the final sentence on Page 211 was highlighted: “It is no accident, then, that every single major change effort we know about has depended on teams.”

 

Through landmark business reconstruction and major wars my father had significant life experience leading and participating in successful teams. He must have come away from those experiences with an understanding of how major change is conjoined with well-organized teamwork. At age 93, the concept of digital transformation was a mystery to him, but the strategy necessary for such radical transformation was very familiar: Major change requires visionary leadership, well-orchestrated collaboration, and flexible innovation.

 

History can teach us a lot about successful collaboration. That connection came through at a ASAP BioPharma Conference in a session on “Alliance Management  Learnings from Great Leaders,” led by Harm-Jan Borgeld, head of alliance management at Merck KGaA;  David Thompson, CSAP, chief alliance officer at Eli Lilly and Company; Steven Twait, CSAP, vice president, alliance and integration management at AstraZeneca. The three alliance professionals probed questions about the “Big Three” WWII alliance led by Winston Churchill,  Franklin Delano Roosevelt, and Joseph Stalin—and how history’s lessons learned relate to today’s strategic alliances.

 

When designed and executed well, alliances can resolve conflict, innovate solutions, win wars, and rejuvenate flagging companies. Collaboration can even streamline services in the public sector and define the  workplace cultures of successful 21st century companies like Jazz Pharmaceuticals. For my father’s generation and for ours, it still comes down to inspired leaders and engaged executives who grapple with change by fostering a culture of teamwork and collaboration— and embrace partners along their journey forward. My dad would recognize this approach as “an inevitable combination.” 

Tags:  Alliances  AstraZeneca  Collaboration  David Thompson  Eli Lilly and Company  Harm-Jan Borgeld  Innovation  Jazz Pharmaceuticals  Merck KGaA  Steve Twait 

Share |
PermalinkComments (0)
 

Q2 2018 Strategic Alliance Magazine: The Culture of Jazz (Pharmaceuticals); a Massive Dutch Cross-agency Alliance; Award-winners—Past and Present; Three ASAP Fall Events

Posted By Cynthia B. Hanson, Wednesday, September 19, 2018
Updated: Monday, September 17, 2018

When the culture of a company really sings, it’s worth exploring the unifying elements. That’s what John W. DeWitt, ASAP Media and Strategic Alliance Magazine Editor and Publisher, explored in the Q2 2018 issue’s cover story, “Choose Culture First: How to Build a Collaborative Enterprise from the Ground Up—and Treat Every Partner Well.” DeWitt probes the underpinnings of Jazz Pharmaceutical in an interview with Cofounder and CEO Bruce Cozadd, and the company’s head of alliance management, Ann Kilrain. Culture, collaboration, and consistent partnering behaviors are integral to Jazz’s success, which is focused on sleep hematology/oncology solutions. “People judge you all the time, and what’s important is how you behave all the time,” says Kilrain during a captivating discussion that emphasizes how consistency and integrity are interwoven into the company culture. Also in this issue’s Up Front, “The Sound of Success,” President and CEO of ASAP, Michael Leonetti, reiterates that point with The Four Cs of Alliance Leadership: Communication, Culture, Collaboration, Compromise. In collaborative leadership, “leaders model their organization’s values and … can impact the culture of an organization,” he writes.  

A second cover story focuses on managing the collaboration of three big government agencies in The Netherlands. In “How an Alliance Matured from Chaos into Award-winning Order,” Diantha Croese, alliance manager at the Dutch Alliances on Data, and Menno Aardewijn, business consultant at the Dutch National SSA, discuss how they tamed a giant, unwieldy cross-agency collaboration between the Dutch IRA, Social Security Administration, and Statistics Netherlands. The management required incredible perseverance as well as “disruption, adap­tation, and overcoming sizable resistance,” and an intricate framework to establish cooperation and financial order between the agencies. Assigned the task of coordi­nating the collection of data about tax revenues, wages, benefits, and corresponding data for the Dutch gov­ernment, they streamlined financial data for the Dutch society while lowering administra­tive costs for employers and operating costs for the alliance partners.

Two other articles in this issue probe the question of what constitutes ASAP award-winning alliance behaviors. First is an article about the 2018 ASAP Alliance Excellence Awards, where seven companies won the four ASAP awards for remarkable accomplishments and exemplary conduct. The second article zeros in on the winner of the 2018 ASAP Alliance for Corporate Responsibility Award, which was presented this year to Cisco and Dimension Data for their celebration of 25 years of partnering with 25 altruistic service projects. The article highlights company employees and their voluntary contributions around the world, which range from education opportunities for girls in Sudan to community bicycles for school children in Thailand.

The Member Spotlight also focuses on the 2018 Individual Alliance Excellence Award winner Julphar in  “Breaking Boundaries in the Pharmaceutical Industry.” Along with pharmaceutical partner MSD, Julphar strategized to make a major difference in seven therapeutic areas for six countries in the Middle East and North Africa region. Julphar’s strategic alliance team consists of in­dividuals from diverse backgrounds whose combined skillsets and experience are viewed as critical to helping the company develop and sustain strong strategic alliances in a different area of the world to create the unique DUNES alliance.

Looking back, this issue also provides a roundup of the 2018 ASAP Global Alliance Summit in “The In-Demand, On-Demand World of Alliance Management, as Portrayed by the 2018 Summit Speakers.” The article captures the essential points of the keynote address and four plenary talks. Looking forward, “Circumnavigate the Globe this Fall With ASAP Conference Offerings” provides a synopsis of ASAP offerings this fall with a review of seminal topics for the three events: The BioPharma Conference, Tech Partner Forum, and European Alliance Summit.

For some hard-hitting findings, turn to Eli Lilly and Company’s Editorial Supplement “Common Value Inflection Points in Pharmaceutical Alliances.” Finding and understanding key inflection points can reveal a lot about your alliance and help alliance managers make good decisions, the article purports. It then does a deep dive into the topic with corroborating data and methodologies.

Finally, The Close relates a personal story about a former World War II Marine’s experience working at the Ford Motor Company in the 1950s during a time of great transition and innovation. “A Lesson From the Whiz Kids: Change and Teams‘An Inevitable Combination’” points out how teams have played an integral role in every major change throughout history. Whether political upheaval or disruption in business, it takes a combination of inspired leadership, engaged executives, collaboration, and a culture of teamwork to bring about a seismic shift. 

Tags:  2018 ASAP Alliance Excellence Awards  Ann Kilrain  ASAP BioPharma Conference  ASAP European Alliance Summit  ASAP Tech Partner Forum  Bruce Cozadd  Collaborative Enterprise  Culture First  Eli Lilly and Company  inflection points  Jazz Pharmaceutical  Julphar  MSD  Partnering Well  Strategic Alliance Magazine 

Share |
PermalinkComments (0)
 

‘You Give Me a Buck, and We Give You Back Three’: Pharma Partnering Leaders Discuss Roles—and the Value of Alliance Management

Posted By Genevieve Fraser, Friday, April 13, 2018
Updated: Wednesday, April 11, 2018

The evolving roles of alliance executives—and capturing the value of the alliance function—were among the many topics that emerged as during the Tuesday, March 27 leadership panel discussion, “Driving Alliance Excellence into the Future,” moderated by Andy Eibling, CSAP, former Covance vice president of alliances, at the ASAP 2018 Global Alliance Summit, “Propelling Partnering for the On-Demand World: New Perspectives + Proven Practices for Collaborative Business,” March 26-28, 2018. Fort Lauderdale, Florida, USA.

 

Pharma executives joining Eibling for the discussion included Casey Capparelli, global product general manager in oncology at Amgen; Nancy Griffin, CA-AM, vice president and head of alliance management, global business development & licensing at Novartis; Mark Noguchi, vice president and global head, alliances and asset management, at Roche; and David S. Thompson, CA-AM, chief alliance officer, Eli Lilly and Company. (Editor’s Note: See the forthcoming April 2018 edition of eSAM Plus for more coverage of this fascinating leadership discussion.)

 

When Eibling threw out the topic of alliance management’s role in acquisitions, mergers, and divestments, and business development and licensing, he noted, “You need to differentiate between a stop and start in terms of divestments. Divestments can be ongoing. Someone in the group manages the ongoing process.”

 

Capparelli: In Amgen that holds true for small acquisitions, but large complex acquisitions need to be managed separately.

 

Thompson: You need to look to someone else to run a large acquisition.

 

Eibling: There’s lots happening in the pharma world today, but will it continue?

 

Thompson: There are more and more partnerships. The trend grows and grows. Today each alliance manager is involved with 20 to 30 alliances. How do you manage ever increasing volume? It’s hard to predict if something will come to fruition.

 

Eibling: Let’s look at the role of the alliance manager, and how it has shifted between project management and alliance management. Alliance management and project management need to be connected at the hip and carve out space through the partnership management team. There are three roles in a partnership management team. The question is who drives those team meetings? Who is accountable? Does the project manager manage the success of the alliance?

 

Thompson: Most M&A integration gets done in 100 days. The work looks the same except it’s compressed. It takes 100 days to swallow an alliance. It’s at a pace you need in an M&A.

 

Capparelli: Deal making is a transactional approach, but building trust generates respect.

 

Griffin: You build an operating model in the core so that you build consistent capabilities.

 

Noguchi: The Roche alliance group is modeled after Lilly. The skill set is there but compressed.

 

Eibling: There’s a shift between deal makers and an alliance manager with a partner. No one understands the dynamics as well as an alliance manager. With ever expanding projects, it’s the alliance manager who understands motivations and how to construct the alliance and M&A deal.

“Let’s look at value,” Eibling said, wrapping up the panel discussion. “How do you capture the value of alliance management? How do you define value?” he asked Thompson.

“Alliances are not efficient but effective,” Thompson asserted.

 

“Fear is a great motivator,” he continued. “I’ve seen too many alliances go out of existence. They focused on relationship management but didn’t expand beyond that to the legal and business risk. That contributed to their demise. They didn’t feel valued in the organization. So, in times of hardship, they’re an easy target to eliminate,” he explained.

 

“We saw it happening and so became open about our model. We measure continuation. We are adjudicated by leadership. It’s valuable to talk about your own contributions. You get the [internal] client you’re supporting to agree based on what they think—what they value or don’t value. Is this a risk reduction or efficiency game? You build to be efficient but it’s the face-to-face that often counts.  As for monetizing the value of alliance management, it’s simple. You give me a buck, and we give you back three.”

Tags:  acquisitions  alliance management  alliance manager  Amgen  Andy Eibling  Casey Capparelli  David S. Thompson  Eli Lilly and Company  leadership  M&A  M&A integration  Mark Noguchi  Nancy Griffin  Novartis  partner  partnerships  Pharma executives  project manager  Roche 

Share |
PermalinkComments (0)
 
Page 1 of 4
1  |  2  |  3  |  4
For more information email us at info@strategic-alliances.org or call +1-781-562-1630